Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

October 01, 2007 (Vol. 27, No. 17)

Producing Biologics Less Expensively

Gleaning Greater Yields with Novel Approaches and Fine-tuned Tools Is One Solution

  • Protein-based drugs are luxury goods, according to François Arcand, CEO, ERA Biotech (www.erabiotech.com). “Since most have the same market size as Cartier watches, I believe no health system in the world has the financial means to supply its general population with drugs made in mammalian cells. They are just ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.